Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieSep 18, 2025

Wharton's Jelly Stem Cells as a Key Resource for Tissue Repair and Regenerative Medicine

Regenerative Health Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 7, 2026

Abstract

Wharton's jelly-derived stem cells may offer a promising alternative to embryonic stem cells in regenerative medicine.

Wharton's jelly contains mesenchymal stem cells with a high proliferation rate.
These stem cells demonstrate multilineage differentiation potential, meaning they can develop into various cell types.
Immunomodulatory properties of Wharton's jelly-derived stem cells may help in reducing immune responses in therapies.
Potential applications include treatment for neurodegenerative disorders, cardiovascular diseases, and musculoskeletal injuries.
The use of Wharton's jelly mesenchymal stem cells signifies a shift toward more ethically acceptable sources in cell-based therapies.

Simplified

Regenerative medicine is a rapidly evolving field that aims to restore or replace damaged tissues using various approaches, including stem cell therapy. While embryonic stem cells possess pluripotency, their application is ethically controversial due to the destruction of embryos. Consequently, adult tissues and perinatal sources, such as the umbilical cord tissue, have gained attention as appealing alternatives. Wharton's jelly, a gel-like connective tissue found in the umbilical cord, has emerged as a prominent source of stem cells for regenerative medicine and tissue engineering. This is due to its high proliferation rate, multilineage differentiation potential, and immunomodulatory properties. The unique properties of Wharton's jelly derived mesenchymal stem cells (WJ-MSCs) have been identified as a promising factor in developing innovative therapeutic solutions for various medical conditions, including neurodegenerative disorders, cardiovascular diseases, and musculoskeletal injuries. The integration of Wharton's jelly mesenchymal stem cells into regenerative medicine and tissue engineering represents a paradigm shift in the development of cell-based therapies.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PubMed

Wharton's Jelly Stem Cells as a Key Resource for Tissue Repair and Regenerative Medicine

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week: